儿科体重管理中回避超说明书用药的双重标准
文章指出儿童肥胖是慢性病,但除生活方式干预和减重手术外治疗选择有限。对比成人,美国FDA批准用于青少年的抗肥胖药物很少。作者通过一例患者说明,在生活方式干预失败时超说明书用药可能有益,并呼吁更多药物选择和研究。
要点
- 儿童肥胖是慢性病,但获批药物远少于成人。
- 生活方式干预常不足以实现有临床意义的减重。
- 在缺乏获批药物时,合理超说明书用药或可改善结局。
核心结论
- 生活方式干预单独用于儿童青少年常不足以刺激有临床意义的体重下降。
- 在更多FDA批准的抗肥胖药物可用前,儿科医生熟悉负责任地超说明书用药可能帮助更多患者达到减重目标。
- 亟需更多药物治疗选择以帮助儿科患者管理体重并预防或改善未治疗肥胖的并发症。
研究设计与样本
- 本文为论述性文章,包含一例病例描述,未报告研究设计与样本量。
主要发现
- 文章描述了美国FDA批准用于青少年的抗肥胖药物有限,并与成人可用药物进行比较。
- 病例描述了一名体重管理困难并开始出现肥胖并发症的患者。
- 文章提出在生活方式干预失败后超说明书用药可能有益的框架。
关键数值与推荐
- 未报告具体药物名称、剂量、阈值或统计数值。
临床怎么用
- 对已进行生活方式干预但未改善的儿童青少年,可考虑在负责任的前提下超说明书使用抗肥胖药物。
- 儿科医生应熟悉超说明书用药的合理使用以改善临床结局。
局限性
- 未报告具体研究数据、样本量或统计结果。
- 未提供超说明书用药的具体药物选择或监测方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pediatric obesity is now recognized as a chronic disease; yet few treatment options exist besides lifestyle modification therapy and bariatric surgery. We describe the limited availability of United States Food and Drug Administration (FDA)-approved antiobesity medications for adolescents and compare this to what is available for adults. We offer a rationale for off-label prescribing to assist with lifestyle modification therapy. We also highlight the need for more pharmacotherapy options and additional research into novel treatments for pediatric obesity. CASE DESCRIPTION: We describe a patient who is struggling with managing her weight and starting to develop complications of obesity. We offer a framework in which off-label prescribing may be beneficial to patients who have been engaging in lifestyle modification therapy yet fail to see improvement. CONCLUSION: Lifestyle modification therapy is necessary but often insufficient in stimulating clinically meaningful weight loss when used alone in children and adolescents who struggle with weight management. Until more FDA-approved antiobesity medications are available, pediatricians may be able to help more patients achieve weight reduction goals by familiarizing themselves with the responsible use of off-label medications and implementing these tools to improve clinical outcomes. There is a critical need for more pharmacotherapy options to help pediatric patients in managing their weight and preventing or improving the insidious complications resulting from untreated obesity.
引用
- San Giovanni CB, Sweeney B, Skelton JA, et al. Aversion to Off-label Prescribing in Clinical Pediatric Weight Management: The Quintessential Double Standard. J Clin Endocrinol Metab. 2021. PMID: 33901290. doi:10.1210/clinem/dgab276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。